Newswise — In a true example of bench-to-bedside science, researchers at UC San Diego have identified the cause of a rare skin disorder, disabling pansclerotic morphea, and swiftly identified a treatment that dramatically improved patients’ symptoms.
The scientists discovered that the patients have an overactive version of a protein called STAT4, and that the drug ruxolitinib improved patients’ rashes and ulcers.
The results were published in the New England Journal of Medicine.
University of California San Diego
Source link